An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer

The anaplastic lymphoma kinase (alk) gene on chromosome 2 encodes a receptor tyrosine kinase protein essential for key signaling pathways regulating cell proliferation and differentiation. Mutations in alk have been implicated in multiple cancers, including non-small cell lung cancer (NSCLC) and ana...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Richard Junior Zapata Dongo, Julio A. Poterico, Diletta Fontana, Luca Mologni, Carla Alvarez-Chacon, Juan Rojas-Armas, Jaeson Calla
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2025-06-01
coleção:	Frontiers in Pharmacology
Assuntos:	ALK binding energy deleterious cancer lorlatinib molecular docking
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1605314/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!